Title: A Study on Role of Neo adjuvant Chemotherapy in Locally Advanced Carcinoma of Breast
Authors: Dr Vinaya K Ambore, Dr Mohammed Siddique J A, Dr Ali Zaid Anwar, Dr Tejashree S Borade
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.144
Abstract
Aims and Objectives: To evaluate the role of Neo adjuvant Chemotherapy in Locally Advanced Carcinoma of Breast along with its incidence, to study different regimens and effect of each cycle on tumour and to study the common side effects
Material and Methods: A case control study was done having Locally Advanced Breast Cancer in a tertiary care hospital, medical record of patients from November 2013 to November 2015 was accessed in a total of 42 patients.
Results: It showed that the most common age group of incidence was 45-54 years and 88.6% were multiparous. Upper outer quadrant was involved in most cases 54.5 % followed by lower quadrant 13.6%. 75 % of cancers were found to be IDC NOS Type. Most common regimen used was FAC leading to most common complication Nausea followed by CMF whose most common complication was alopecia followed by AC were both nausea and alopecia were common .There was a significant decrease in tumour size after chemotherapy (6.9 +/- 1.12 to 3.62 +/- 1.01,p value <0.05).MRM was the most common surgery done followed by simple mastectomy. Overall, the CMF regimen proves more effective than any other regimen as it provides good resect ability of the tumour as compared to other regimen.
Conclusion: There was significant decrease in tumour size after NACT making a select group of patient suitable for conservative surgeries but long term cure rates are still <50 %.
Keywords: Neo adjuvant chemotherapy, Locally Advanced Breast Cancer.
References
1. Olivotto IA, Chua B, Allan SJ, et al. Long-term survival of patients with supra-clavicular metastases at diagnosis of breast cancer. J Clin Oncol 2003;21:851–4.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011.
3. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcino-ma of the breast, 2004; 100:2512-32.
4. Uroos Fatima, Rana Sherwani, Tamkin Khan, Sufian Zaheer, Foetal Autopsy-Categories and Causes of Death, J Clin Diagn Res, 2014 Oct: 8(10).
5. Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. Semin Oncol 2009; 36:237-49.
6. Sabahattin Aslan, MD, Abdullah Çetin, MD, Breast cancer infiltration by cardiothoracic surgery, Can J Surg. 2009 Jun; 52(3): E66–E68.
7. Agrawal Kapil H1, Rajderkar SS2, Clinico-Epidemiological Profile Of Female Breast Cancers and Its Important Correlates: A Hospital Based Study, National Journal of Community Medicine Vol 3 Issue 2 April-June 2012; 316-20.
8. Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands, J Natl Cancer Inst. 1994 Nov 2;86(21):1600–1608.
9. Graishar WJ, Tjulndin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23(31): 7794-80.
10. Sutima L, Norasate S, Krittiya K. Assoc-iation between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients, J Breast Cancer 2014 December; 17(4): 376-385.
11. Deo, S.V.S., Bhutani, M., Shukla, N. K.,et al, Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).(2003), J. Surg. Oncol., 84: 192–197.